

The estimated consolidated loss attributable to equity shareholders of the Company for the year ended December 31, 2020 is set out in the section headed “Financial Information – Loss Estimate for the Year Ended December 31, 2020” in this prospectus.

A. BASES

We have prepared our estimate of the consolidated loss attributable to equity shareholders of the Company for the year ended December 31, 2020 based on (i) the audited consolidated results of the Group for the seven months ended July 31, 2020 as set out in the Accountants’ Report in Appendix I to the Prospectus; and (ii) the unaudited consolidated results based on the management accounts of the Group for the five months ended December 31, 2020. Our loss estimate has been prepared on a basis consistent in all material respects with the accounting policies normally adopted by the Group as set out in our Accountants’ Report, the text of which is set out in Appendix I to this prospectus. In the absence of unforeseen circumstances, the estimated consolidated loss attributable to equity shareholders of the Company for the year ended December 31, 2020 will be no more than RMB400.0 million.

B. LETTER FROM THE REPORTING ACCOUNTANTS

The following is the text of a letter, prepared for the inclusion in this prospectus, received from KPMG, Certified Public Accountants, Hong Kong, the reporting accountants of our Company, in relation to our Group's loss estimate for the year ended December 31, 2020.



8th Floor
Prince's Building
10 Chater Road
Central
Hong Kong

January 26, 2021

The Directors
MicroPort CardioFlow Medtech Corporation

J.P. Morgan Securities (Far East) Limited
Citigroup Global Markets Asia Limited
China International Capital Corporation Hong Kong Securities Limited

Dear Sirs,

MicroPort CardioFlow Medtech Corporation ("the Company")

Loss Estimate for Year Ended December 31, 2020

We refer to the estimate of the consolidated loss attributable to equity shareholders of the Company for the year ended December 31, 2020 ("the Loss Estimate") set forth in the section headed "Financial Information" in the prospectus of the Company dated January 26, 2021 ("the Prospectus").

Directors' Responsibilities

The Loss Estimate has been prepared by the directors of the Company based on the audited consolidated results of the Company and its subsidiaries (collectively referred to as "the Group") for the seven months ended July 31, 2020 and the unaudited consolidated results based on the management accounts of the Group for the five months ended December 31, 2020.

The Company's directors are solely responsible for the Loss Estimate.

Our Independence and Quality Control

We have complied with the independence and other ethical requirements of the Code of Ethics for Professional Accountants issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"), which is founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behavior.

The firm applies Hong Kong Standard on Quality Control 1 “Quality Control for Firms That Perform Audits and Reviews of Financial Statements, and Other Assurance and Related Services Engagements” issued by the HKICPA and accordingly maintains a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

Reporting Accountants’ Responsibilities

Our responsibility is to express an opinion on the accounting policies and calculations of the Loss Estimate based on our procedures. We conducted our engagement in accordance with Hong Kong Standard on Investment Circular Reporting Engagements 500 “Reporting on Profit Forecasts, Statements of Sufficiency of Working Capital and Statements of Indebtedness” and with reference to Hong Kong Standard on Assurance Engagements 3000 (Revised) “Assurance Engagements Other Than Audits or Reviews of Historical Financial Information” issued by the HKICPA. Those standards require that we plan and perform our work to obtain reasonable assurance as to whether, so far as the accounting policies and calculations are concerned, the Company’s directors have properly compiled the Loss Estimate in accordance with the bases adopted by the directors and as to whether the Loss Estimate is presented on a basis consistent in all material respects with the accounting policies normally adopted by the Group. Our work is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing issued by the HKICPA. Accordingly, we do not express an audit opinion.

Opinion

In our opinion, so far as the accounting policies and calculations are concerned, the Loss Estimate has been properly compiled in accordance with the bases adopted by the directors as set out in Appendix IIB of the Prospectus and is presented on a basis consistent in all material respects with the accounting policies normally adopted by the Group as set out in our accountants’ report dated January 26, 2021, the text of which is set out in Appendix I of the Prospectus.

Yours faithfully,

KPMG*Certified Public Accountants*

Hong Kong

C. LETTER FROM THE JOINT SPONSORS

The following is the text of a letter, prepared for the inclusion in this prospectus, received from J.P. Morgan Securities (Far East) Limited, Citigroup Global Markets Asia Limited and China International Capital Corporation Hong Kong Securities Limited, the Joint Sponsors, in relation to our Group's loss estimate for the year ended December 31, 2020.

J.P.Morgan

January 26, 2021

The Board of Directors
MicroPort CardioFlow Medtech Corporation
P.O. Box 10008
Willow House, Cricket Square
Grand Cayman, KY1-1001
Cayman Islands

Dear Sirs,

We refer to the estimate of the consolidated loss attributable to equity shareholders of MicroPort CardioFlow Medtech Corporation (the “Company”) for the year ended December 31, 2020 (the “Loss Estimate”) set forth in the section headed “Financial Information—Loss Estimate for the Year Ended December 31, 2020” in the prospectus of the Company dated January 26, 2021 (the “Prospectus”).

The Loss Estimate, for which the directors of the Company (the “Directors”) are solely responsible, has been prepared by the Directors based on (i) the audited consolidated results of the Company and its subsidiaries (collectively referred to as the “Group”) for the seven months ended July 31, 2020 as set out in the Accountants’ Report in Appendix I to the Prospectus and (ii) the unaudited consolidated results based on the management accounts of the Group for the five months ended December 31, 2020.

We have discussed with you the bases made by the Directors as set out in Appendix IIB to the Prospectus, upon which the Loss Estimate has been made. We have also considered the letter dated January 26, 2021 addressed to yourselves and ourselves from KPMG, *Certified Public Accountants*, regarding the accounting policies and calculations upon which the Loss Estimate has been made.

On the basis of the information comprising the Loss Estimate and on the basis of the accounting policies and calculations adopted by you and reviewed by KPMG, *Certified Public Accountants*, we are of the opinion that the Loss Estimate, for which you as the Directors are solely responsible, has been made after due and careful enquiry.

For and on behalf of

J.P. Morgan Securities (Far East) Limited**Raymond Wai Cheuk Lau***Executive Director***Citigroup Global Markets Asia Limited****Chao Lu***Managing Director***China International Capital Corporation****Hong Kong Securities Limited****Barry Chan***Managing Director***Jin Liang***Managing Director*